Dacarbazine

• IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR’S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE META… Not authorised
  2023-506686-66-00 Phase II/III 1 country Ideaya Biosciences Inc.
• Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients … Pending
  2024-517295-37-00 Phase III 1 country University Of Cologne
• Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma (N-BRAVE) Pending
  2026-525263-41-00 Phase III 1 country Polska Grupa Badawcza Chloniakow
• SUPRAME - ACTengine® IMA203 vs. investigator’s choice of treatment in previously treated, unresectable or metastatic cutaneous melanoma Recruiting
  2024-517062-42-00 Phase III 3 countries Immatics US Inc.
• A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE OR METASTATIC NRAS MUTANT CUTANEOUS MELANOMA COMPARI… Recruiting
  2024-511404-17-00 Phase III 10 countries Erasca Inc.
• A study to test the effect of chemotherapy before surgery compared to surgery alone in patients with high risk retroperitoneal sarcoma. Recruiting
  2023-505261-84-00 Phase III 10 countries European Organisation For Research And Treatment Of Cancer
• Tarlatamab vs standard of care chemotherapy in patients with pre-treated advanced, pulmonary or gastroenteropancreatic poorly differentiated… Recruiting
  2024-515948-23-00 Phase III 1 country Intergroupe Francophone De Cancerologie Thoracique
• Phase Ib study combining dinutuximab beta with induction chemotherapy regimens in patients with newly diagnosed high-risk neuroblastoma Recruiting
  2023-509673-22-00 Phase I/II 7 countries Prinses Maxima Centrum voor Kinderoncologie B.V.
• IDE196 (Darovasertib) in Combination with Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Recruiting
  2023-506686-66-01 Phase II/III 7 countries Ideaya Biosciences Inc.
• RADAR: A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previousl… Recruiting
  2022-500031-37-00 Phase III 7 countries University College London
• PHASE III TRIAL INVESTIGATING BENEFIT OF INTENSIFIED PERI-OPERATIVE CHEMOTHERAPY WITHIN HIGH-RISK CINSARC PATIENTS WITH RESECTABLE SOFT-TISS… Recruiting
  2023-509489-39-00 Phase III 1 country Institut Bergonie
• Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma Ended
  2022-500571-32-00 Phase II 1 country University Of Cologne
• Efficacy and Safety of L19TNF in Previously Treated Patients With Advanced Stage or Metastatic Soft-tissue Sarcoma Ended
  2024-512704-20-00 Phase II 5 countries Philogen S.p.A.
• A phase II trial of MK-3475 (pembrolizumab) in children and young adults with classical Hodgkin lymphoma Ended
  2023-504821-38-00 Phase II 8 countries Merck Sharp & Dohme LLC
• Phase 2 study of pembrolizumab and chemotherapy in participants with classical Hodgkin Lymphoma that has just been diagnosed Ended
  2022-501615-14-00 Phase II 4 countries Merck Sharp & Dohme LLC
• Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Ended
  2023-503387-16-00 Phase II 4 countries Seagen Inc.
• A Phase 2, single arm study on dacarbazine (DTIC) followed by immunotherapy re-challenge in unresectable or metastatic melanoma with primary… Ended
  2024-517065-16-00 Phase II 1 country Universitaetsklinikum Erlangen AöR
• Safety and efficacy of IMCgp100 versus Investigator’s Choice in advanced uveal melanoma Ended
  2024-517290-24-00 Phase II 5 countries Immunocore Limited
• HD21 Ended
  2024-518022-33-00 Phase III 6 countries University Of Cologne
• Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma Ended
  2023-506419-16-00 Phase III 9 countries Takeda Development Center Americas Inc.

Showing 1–20 of 20 trials